Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Behandeling stadium II-III niet-kleincellig longcarcinoom gaat flink op de schop
apr 2024 | Immuuntherapie, Longoncologie